BioCentury
ARTICLE | Company News

Aptein, Cambridge Antibody deal

June 7, 1999 7:00 AM UTC

CAT issued 1.1 million common shares valued at $5 million to Aptein shareholders to complete the purchase of Aptein for a total of $11 million (see BioCentury, June 29, 1998). The issue was triggered ...